^
    5d
    Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    14d
    OV-AML-1231: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, OncoVerity, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD4 (CD4 Molecule)
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    14d
    CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target. (PubMed, Leukemia)
    Furthermore, the ADCC-enhanced anti-CD70 antibody, cusatuzumab, demonstrated high efficacy in treating myeloma in xenotransplantation models. Collectively, these findings underscore the critical role of CD70/CD27 signaling in activating MAPK/ERK and Wnt pathways essential for MM progression. Targeting CD70 with blocking or ADCC-enhanced antibodies represents a promising therapeutic strategy, particularly for advanced MM stages characterized by high CD70 expression.
    Journal • IO biomarker
    |
    CD70 (CD70 Molecule) • CD27 (CD27 Molecule)
    |
    cusatuzumab (ARGX-110)
    17d
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Completed, OncoVerity, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    azacitidine • cusatuzumab (ARGX-110)
    1m
    Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Pan tumor
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    2ms
    A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (clinicaltrials.gov)
    P1, N=280, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity. (PubMed, J Immunother Cancer)
    CD70 is a promising target for NK cell-based immunotherapy in AML. However, IFN-γ-dependent upregulation of HLA molecules on AML cells contributes to resistance to ADCC. These findings underscore the need for rationale combination strategies in clinical trials to overcome this inducible immune escape mechanism.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • HLA-E (Major Histocompatibility Complex, Class I, E) • HLA-C (Major Histocompatibility Complex, Class I, C) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    PF-08046040
    8ms
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Trial completion date: Aug 2025 --> May 2026
    Trial completion date
    |
    azacitidine • cusatuzumab (ARGX-110)
    10ms
    Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. (PubMed, Front Immunol)
    These findings characterize ADP-520 as a first-in-class, CD70-targeted, fratricide-resistant autologous TRuC T-cell therapy leveraging native TCR signaling combined with constitutive IL-15 signaling to impart T cells with enhanced persistence, tumor penetration, and antitumor efficacy. This makes ADP-520 a promising cell immunotherapy candidate for clinical development, with the potential to overcome hurdles intrinsic to the treatment of solid tumors.
    Journal • IO biomarker
    |
    CD70 (CD70 Molecule) • IL15 (Interleukin 15)
    10ms
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Recruiting, Molecular Partners AG | N=70 --> 249 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    11ms
    SGNS70-101: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (clinicaltrials.gov)
    P1, N=178, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • PF-08046040
    12ms
    ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, OncoVerity, Inc. | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)